
argenx will acquire Unnatural Products for up to $1.15B, bringing oral macrocyclic peptides and new formulation challenges to its antibody portfolio.
FDA has found several pharmaceutical companies not maintaining Class 100 conditions within transfer carts. The author discusses an approach for designing a transfer cart that will satisfy such conditions.
over 23 years ago
BIO Updateover 23 years ago
An Update on Osmotic Drug Deliveryover 23 years ago
New FDA Initiatives Aim to Spur Innovationover 23 years ago
Interphex Serves as a Showcase for New Materials and Machinesover 23 years ago
August 2003over 23 years ago
In the Spotlight August 2003





